Home > Healthcare > Analytical Instruments > Elemental Analysis > Label-free Array Systems Market

Label-free Array Systems Market Size

  • Report ID: GMI9649
  • Published Date: May 2024
  • Report Format: PDF

Label-free Array Systems Market Size

Label-free Array Systems Market size was valued at around USD 1.4 billion in 2023 and is estimated to grow at 7.2% CAGR from 2024 to 2032. Label-free array systems are advanced analytical platforms used for detecting and characterizing biomolecular interactions without the need for fluorescent, radioactive, or enzymatic labels. These systems measure changes in physical properties such as mass, refractive index, or electrical impedance to provide real-time data on binding events between biomolecules, such as proteins, nucleic acids, or small molecules.


The increasing drug discovery and development activities is a significant driver for the label-free array systems market. For instance, according to the National Institutes of Health, in 2023, these systems allow for high-throughput screening of potential drug candidates, enabling researchers to quickly and efficiently identify promising compounds. This capability is crucial in the early stages of drug discovery where large libraries of molecules are tested for biological activity. Furthermore, these systems provide real-time monitoring of biomolecular interactions without the need for labels that can alter the behavior of the molecules being studied.

Furthermore, increasing drug discovery services, advancement in drug discovery outsourcing services, advancements in biotechnology and life sciences research, surge in drug screening, government initiatives and funding, and increasing education & awareness, are the promoting factors advancing the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global label-free array systems industry size was valued at USD 1.4 billion in 2023 and is estimated to grow at 7.2% CAGR from 2024 to 2032 due to increasing drug discovery and development activities and rising cases of chronic and infectious diseases.

The surface plasmon resonance (SRP) segment in the market is estimated to account for USD 669.2 million by 2032 because SRP technology offers sensitive and label-free detection of biomolecular interactions.

The drug discovery segment of the label-free array systems market accounted for USD 483.6 million in 2023 due to screening large libraries of compounds to identify potential drug candidates and the ability to conduct real-time analysis.

Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Corning Incorporated, Danaher Corporation, F. Hoffmann-La Roche AG, Illumina, Inc., Merck KGaA, Meso Scale Diagnostics (MSD), Nanion Technologies, and Pall Corporation, among others.

Label-free Array Systems Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 237
  • Countries covered: 23
  • Pages: 150
 Download Free Sample